Today: 19 May 2026
Paladin Energy share price dips into weekend as uranium’s $100 test looms for Monday
1 February 2026
1 min read

Paladin Energy share price dips into weekend as uranium’s $100 test looms for Monday

Sydney, February 1, 2026, 17:22 AEDT — Market closed.

  • Paladin Energy shares fell 2.1% to close at A$13.84 on Friday, slipping from a peak of A$14.44.
  • Uranium climbed back above $100 a pound, drawing trader attention to spot-price volatility and fund purchases.
  • Paladin’s interim results, set for February 12, mark the next key date for investors.

Paladin Energy’s shares closed 2.1% lower at A$13.84 on Friday, having reached A$14.44 earlier in the day. The Australian Securities Exchange is closed for the weekend, with trading scheduled to pick up again on Monday.

This shift is significant now as uranium-related stocks have started trading like a macro play once more: headlines, flows, and a spot market with sparse data that can shift quickly. That’s been enough to jolt equities within hours.

Spot uranium climbed back above $100 a pound this week following new purchases and a cash raise by Sprott Physical Uranium Trust, according to a report from Investing News Network. Guy Keller described the move as entering “a new range for the spot price,” calling $100 “a new floor” for the coming 12 months. Investing News Network (INN)

Uranium pricing remains murky compared to many other commodities. Cameco points out that contracts are hammered out behind closed doors between buyers and sellers, not on a public exchange. That lack of transparency can make published reference prices swing sharply, especially when funds step in to buy.

Other ASX uranium stocks slipped by Friday’s end. Boss Energy dropped 4.9% to finish at A$1.95, and Deep Yellow slipped 2.4% to A$2.84.

Paladin’s focus remains on output, costs, and the uranium market. In its December-quarter report, the company revealed it produced 1.23 Mlb of U3O8 (triuranium octoxide, the typical uranium concentrate) and sold 1.43 Mlb. It’s projecting full-year production near the top of its 4.0–4.4 Mlb guidance. The company also announced interim financial results will be released on Feb. 12. CEO Paul Hemburrow said he was “delighted” with the ramp-up at the Langer Heinrich Mine in Namibia. Additionally, Paladin confirmed it will continue to defend against a shareholder class action.

Uranium volumes and realised prices often swing from one quarter to the next, driven by changes in contract terms and delivery schedules. Investors usually see “strong sales” and “strong production” as separate cues, particularly with the spot market setting the tone.

The downside is clear-cut: if uranium dips below triple digits again and demand from physical funds fades, the momentum in uranium miners could unravel fast. A hiccup in operations during ramp-up would only deepen the slide.

As trading resumes, the key question is whether Friday’s dip sparks another wave of profit-taking or simply marks a brief halt. Uranium price news is expected to drive the action either way.

Paladin’s next key moment arrives February 12, with interim financial results due. Investors will be watching closely for updates on production growth, costs, and contracted sales.

Stock Market Today

  • Q1 Earnings Review: Knowles Outshines Peers in Electronic Components Sector
    May 19, 2026, 6:20 AM EDT. Electronic components & manufacturing sector posted strong Q1 results, with revenues beating analysts' consensus by 3.8% and share prices rising 11% on average. Knowles (NYSE:KN) led within the group, reporting $153.1 million in revenues, up 15.8% year-on-year, surpassing expectations by 3.9%. CEO Jeffrey Niew highlighted solid revenue and earnings per share (EPS) performance. Knowles shares gained 13.4% post-earnings, trading at $35.45. TTM Technologies (NASDAQ:TTMI) posted the best overall quarter with revenues up 30.4%, beating estimates by 6.9%, and shares climbing 16% to $159.48. Sector growth prospects include expanding demand in automotive, healthcare, aerospace, and computing. Risks remain from geopolitical tensions and environmental regulations. Analysts remain cautious but optimistic on the sector outlook.

Latest articles

Hesai Up Premarket After Mercedes Lidar Win, Q1 Profit

Hesai Up Premarket After Mercedes Lidar Win, Q1 Profit

19 May 2026
Hesai Group shares rose 2.68% to $22.60 in U.S. premarket trading after reporting a first-quarter profit and confirming it will supply lidar sensors for Mercedes-Benz Level 3 autonomous models. The company shipped 471,723 lidar units, up 140.9% year-on-year, and posted revenue of RMB680.6 million ($98.7 million). Net income reached RMB18.3 million, reversing a loss from a year earlier.
Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

19 May 2026
Virax Biolabs shares surged 53.1% Monday to $0.2350 and climbed another 17.1% in early Tuesday premarket trading, hitting $0.2751. The rally followed a paid RedChip TV appearance and a May 15 ownership filing showing Armistice Capital with a 4.99% stake. No new clinical or product updates were posted. Trading volume Monday reached about 765.2 million shares.
Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

19 May 2026
Amesite Inc. shares surged 218% to $2.50 in premarket trading after announcing its largest NurseMagic deployment with a 2,700-patient home-care client. The company disclosed $83,332 in quarterly revenue and a $678,061 net loss, with cash at $740,711 before a $2.2 million April financing. Amesite did not reveal the new contract’s value or customer name. Its latest filing cited “substantial doubt” about ongoing operations.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Renesas stock price: Wolfspeed stake update lands days before Feb. 5 earnings
Previous Story

Renesas stock price: Wolfspeed stake update lands days before Feb. 5 earnings

Saks Off 5th liquidation sales begin as Saks Global moves to close 57 stores
Next Story

Saks Off 5th liquidation sales begin as Saks Global moves to close 57 stores

Go toTop